News

Intensity Therapeutics Preclinical Results Show AntiCancer Synergy of INT230-6 with Anti-PD-1 Compounds

Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists

Intensity Therapeutics, Inc. CEO to Speak at the 10th Annual Value-Based Oncology Management Forum

Intensity Therapeutics, Inc.’s Research Selected for Presentation at the 2015 American Association for Cancer Research Annual Meeting

Intensity Therapeutics Selected to Present at BioCentury Future Leaders Conference

Intensity Therapeutics, Inc. to Present at the Biotech Showcase Conference in San Francisco

Intensity Therapeutics, Inc.’s Research Selected for Presentation at the Annual National Cancer Institute Cancer Immunology and Immunotherapy Conference

Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President and Chief Medical Officer

Intensity Therapeutics, Inc. Awarded Cooperative Research and Development Agreement from the National Cancer Institute

Intensity Therapeutics, Inc. to Present at the 2014 NYBIO Annual Conference in New York

Intensity Therapeutics, Inc. to Participate on Cancer Panel at the Wharton DC Innovations Summit

Intensity Therapeutics to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences in New York

Intensity Therapeutics, Inc. to Present at the Life Sciences Summit Conference

Intensity Therapeutics, Inc. Named 2013 Tech Company to Watch

Intensity Therapeutics, Inc. to Present at the Landmark Angels Investor Conference

Intensity Therapeutics, Inc. to Present at the Redefining Early Stage Investments Conference

Intensity Therapeutics, Inc. Designated Qualified Connecticut Business by Connecticut Innovations

Intensity Therapeutics, Inc. to Present at the New York Biotech’s Annual Healthcare Conference

Intensity Therapeutics, Inc. to Present at Life Sciences Venture Summit in New York City

Intensity Therapeutics, Inc. Raises $225,000 in Preseed funding